CanSino Biologics' (HKG:6185) subsidiary CanSino (Shanghai) Biological Research entered into a strategic cooperation framework agreement with deepGeneAI to jointly develop personalized mRNA therapeutic cancer vaccines.
The companies will explore combining CanSino's mRNA vaccine technology with deepGeneAI's tumor neoantigen discovery and design capabilities, according to a Wednesday Hong Kong bourse filing.